Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 4/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.43 |
| ▸ | GRM6 | O15303 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21201087 | 1.00 | TSHR (0.50) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL28795751 | 0.87 | TSHR (0.53) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL15675484 | 0.86 | TSHR (0.48) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL8208668 | 0.83 | L3MBTL1 (0.46) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL7009326 | 0.82 | TSHR (0.52) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL11432821 | 0.79 | TSHR (0.61) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL384083 | 0.79 | TSHR (0.61) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL7822123 | 0.78 | ACP3 (0.51) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL6745214 | 0.77 | L3MBTL1 (0.62) | TSHRLMNAACP3L3MBTL1MEN1 | |
| SCHEMBL7110594 | 0.77 | L3MBTL1 (0.62) | TSHRLMNAACP3L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | TSHR 4165/4885LMNA 2103/4885ACP3 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.